Trials / Completed
CompletedNCT00892931
Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme
Phase 2 Study of Azixa (MPC-6827) for the Treatment of Patients With Recurrent Glioblastoma Multiforme
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Myrexis Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma multiforme
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azixa | 3.3 mg/m2 of Azixa administered by intravenous infusion over 2 hours once weekly for 3 consecutive weeks every 4 weeks (1 cycle = 4 weeks) |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2011-07-01
- Completion
- 2011-09-01
- First posted
- 2009-05-05
- Last updated
- 2011-10-14
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00892931. Inclusion in this directory is not an endorsement.